Back to News
Market Impact: 0.3
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Both doses of SPY072 reported statistically significant improvement versus placebo on at least one primary endpoint (change from baseline in DAS28-CRP) and key secondary endpoint (ACR20), with additional positive signals on exploratory measures such as ACR50.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Europe's answer to SpaceX set for 25% weekly gain as Ukraine's Starshield limits raise concerns
- CoreWeave shares, bonds headed for steep weekly losses as AI borrowing concerns mount
- Rocket Lab shares price target maintained at $120 by Needham after Neutron delay
- Why is Strategy stock sliding today?
- I watched Nvidia's Jensen Huang work the room in London. He brought big checks — and a blunt message
- Nike's India campus is a long-term growth bet amid turnaround